ASLAN Pharmaceuticals Stock to Reverse Split on Wednesday, July 3rd (NASDAQ:ASLN)

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN)’s stock is scheduled to reverse split on Wednesday, July 3rd. The 1-8 reverse split was announced on Wednesday, July 3rd. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, July 3rd.

ASLAN Pharmaceuticals Stock Performance

NASDAQ:ASLN opened at $0.30 on Monday. ASLAN Pharmaceuticals has a 52 week low of $0.27 and a 52 week high of $3.89. The firm’s fifty day moving average is $0.41 and its 200-day moving average is $0.53. The firm has a market cap of $4.91 million, a P/E ratio of -0.11 and a beta of 1.44.

ASLAN Pharmaceuticals (NASDAQ:ASLN) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.61). As a group, sell-side analysts anticipate that ASLAN Pharmaceuticals will post -2.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $9.00 target price on shares of ASLAN Pharmaceuticals in a research note on Friday, May 3rd. Piper Sandler reaffirmed an “overweight” rating and set a $10.00 price objective (down previously from $15.00) on shares of ASLAN Pharmaceuticals in a research report on Wednesday, March 13th.

ASLAN Pharmaceuticals Company Profile

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases.